Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Trump administration officials are weighing a controversial maneuver aimed at allowing them to block federal funding previously authorized by Congress without lawmakers’ approval. White House budget ...

I now rate Recursion Pharma a sell due to disappointing recent trial updates and uncertain future prospects. REC-4881's phase 2 TUPELO trial showed mixed results, with one patient experiencing a ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Say it isn't so! The HGTV competition series Rock the Block is about to wrap its sixth season in ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...